Healthcare101

 In modern medicine, diagnostics are rapidly moving toward less invasive, more precise, and real-time approaches . One of the most transformative innovations driving this change is liquid biopsy —a technique that is reshaping how diseases, especially cancer, are detected and monitored. The liquid biopsy market is estimated at USD 4.03 billion in 2025 and is projected to reach USD 7.05 billion by 2030, growing at a CAGR of 11.8% during the forecast period.  📌 What Is a Liquid Biopsy? A liquid biopsy is a diagnostic test that analyzes biological markers found in body fluids—most commonly blood—to gather information about a disease. 👉 In simple terms: Instead of surgically removing tissue, doctors can “read” disease signals from a blood sample. These signals may include: Circulating tumor DNA ( ctDNA ) Circulating tumor cells ( CTCs ) Cell-free DNA ( cfDNA ) RNA, proteins, or exosomes Download PDF Brochure: https://www.marketsa...

 The global liquid biopsy market is witnessing robust expansion, driven by rising cancer prevalence and growing demand for non-invasive diagnostics. Valued at US$3.65 billion in 2024 , the market is projected to reach US$4.03 billion in 2025 and is anticipated to grow at a CAGR of 11.8% from 2025 to 2030 , achieving US$7.05 billion by 2030 . The increasing emphasis on early detection and precision medicine, coupled with the ability of liquid biopsies to provide real-time insights into tumor dynamics, underpins this growth. These tests are also gaining popularity in non-invasive prenatal testing and organ transplantation monitoring , further widening their clinical applications. Advancements in next-generation sequencing (NGS) , biomarker identification , and molecular diagnostics have significantly improved the sensitivity and accuracy of liquid biopsy tests. Rising public and private investments in precision oncology and the growing need for early, non-invasive disease detec...

 The liquid biopsy market is revolutionizing the landscape of diagnostics and personalized medicine. Liquid biopsy, a minimally invasive diagnostic technique, detects biomarkers in bodily fluids such as blood, urine, or cerebrospinal fluid. Its ability to offer real-time insights into a patient's condition makes it a preferred choice over traditional tissue biopsies. This article delves into the key trends, advancements, and opportunities shaping the liquid biopsy market. Understanding Liquid Biopsy: A Game-Changer in Diagnostics Liquid biopsy involves analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers . This method enables early cancer detection, monitoring treatment responses, and identifying disease progression. Unlike tissue biopsies, liquid biopsies are non-invasive, reducing patient discomfort and allowing repeated sampling. Key Drivers Fueling the Liquid Biopsy Market Growing Prevalence of Cancer The increasing global burden of c...

  Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™. In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and mon...

  Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™. Liquid Biopsy Market Trends Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Browse in-depth TOC on "Liquid Biopsy Market" 406 - Tables 56 - Figures 343 - Pages North America is the largest regional market for liquid biopsy market. The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the inte...

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™. In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitori...

  Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™. In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and mon...